<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479203</url>
  </required_header>
  <id_info>
    <org_study_id>828195</org_study_id>
    <secondary_id>R01HL139358</secondary_id>
    <nct_id>NCT03479203</nct_id>
  </id_info>
  <brief_title>Acute Effects of E-Cigarette Aerosol Inhalation</brief_title>
  <official_title>Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular Reactivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the acute effects of nicotine free electronic
      cigarette aerosol on vascular function in healthy, non-smokers.

      This study comprises a portion of a larger study comparing results of vascular function in
      nonsmokers to vascular function in healthy smokers chronically exposed to nicotinized
      electronic cigarette aerosol versus conventional cigarettes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is 1) to examine the acute effects of nicotine free e-cigarette
      aerosol on vascular function in healthy, non-smokers and 2) to examine and compare vascular
      function in healthy smokers chronically exposed, at baseline and after 12 months, to
      nicotinized e-cigarette aerosol versus conventional cigarettes as compared to age, gender and
      body mass index-matched nonsmokers. Vascular function (microvascular reactivity via dynamic
      femoral oximetry, arterial hyperemia, femoral artery flow-mediated dilation, central
      pulse-wave velocity, neurovascular reactivity) will be assessed as part of a single
      integrated MRI protocol. The outcome of the project will provide new insight into the acute
      and chronic effects of e-cigarette aerosol inhalation in terms of surrogate markers of
      endothelial dysfunction (EDF), the prime promoter of atherosclerotic cardiovascular disease,
      and aid toward establishment of future public health advisories.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in serum protein levels (micrograms) of inflammatory biomarkers (HMGB-1, RAGE, ICAM, CRP) in non-smoking healthy subjects before and after electronic cigarette aerosol inhalation.</measure>
    <time_frame>Baseline to six hours</time_frame>
    <description>High mobility group box-1 (HMGB1), receptor for advanced glycation end products (RAGE), intercellular adhesion molecule (ICAM1) and C-reactive protein (CRP) will be monitored in serum from subjects by ELISA assays measuring the exact concentration of moieties based on absorbance values emanating from the serum samples. Using standard curves, the amount of these biomarkers will be monitored in the range of nmole or pmole/microgram of serum protein. Measurements will be carried out in triplicate for each sample. Data will be quantified as amount of biomarker/microgram serum protein.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aortic pulse-wave velocity (meters/second)</measure>
    <time_frame>Baseline to six Hours</time_frame>
    <description>Stiffness of aorta</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Femoral artery flow-mediated dilation (% fractional change in cross-sectional area)</measure>
    <time_frame>Baseline to six Hours</time_frame>
    <description>Degree of dilation of femoral artery during hyperemia (the transient increase in blood flow velocity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Washout time (seconds)</measure>
    <time_frame>Baseline to six Hours</time_frame>
    <description>Transit time of desaturated capillary blood from tissue to the imaging location</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upslope (%HbO2/seconds)</measure>
    <time_frame>Baseline to six Hours</time_frame>
    <description>Tissue oxygen resaturation rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overshoot (%HbO2)</measure>
    <time_frame>Baseline to six Hours</time_frame>
    <description>Degree of overcompensatory effect in supply of oxygen after ischemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breath hold index (meters/seconds^2)</measure>
    <time_frame>Baseline to six Hours</time_frame>
    <description>Rate of increase in blood flow velocity in the superior sagittal sinus from intermittent volitional apnea</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Biochemical Markers</condition>
  <arm_group>
    <arm_group_label>Healthy, Non-Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-nicotinized electronic cigarette aerosol (16 2-second long puffs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Electronic Cigarette Aerosol</intervention_name>
    <description>16 two-second-long puffs from a non-nicotinized electronic cigarette.</description>
    <arm_group_label>Healthy, Non-Smokers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ BMI of 18.5 - 30

        Exclusion Criteria:

          -  Cancer

          -  HIV

          -  Mental illness

          -  Overt cardio- or neurovascular disease (prior heart attack, stroke, transient ischemic
             attacks)

          -  Serious arrhythmias

          -  Bronchospastic disease

          -  Upper respiratory tract infection within the past six weeks

          -  Chronic medication or antibiotics

          -  Claustrophobia / contraindications for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix W. Wehrli, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Sexton, B.A.</last_name>
    <phone>215-662-2842</phone>
    <email>kelly.sexton@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pennsylvania Perelman School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Sexton, B.A.</last_name>
      <phone>215-662-2842</phone>
      <email>kelly.sexton@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Felix W Wehrli, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael C Langham, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shampa Chatterjee, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank T Leone, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew A Strasser, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Felix Wehrli</investigator_full_name>
    <investigator_title>Professor of Radiologic Science, Biochemistry and Biophysics</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

